

90.8% of our clients are likely to recommend Kayentis to a colleague or a friend.
Ensure the success of your decentralized clinical trials: select Kayentis!



*Results of a survey conducted on 300+ Kayentis' clients in January 2022
** 2020 recommendation rate = 88.1%

To learn more, please contact us at
sales@kayentis.com

Kayentis
Boston - USA | Maastricht - France | Tokyo - Japan



Download our 2021 customer satisfaction survey

Learn more:



The strengths of electronic Clinical Outcome Assessment (eCOA) versus paper solutions

5 February 2024

In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy

[Read More »](#)



The relevance of ePROs in early phase clinical trials

31 January 2024

Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the

[Read More »](#)



3 considerations to take into account when setting up an eCOA clinical trial

29 January 2024

In a clinical trials environment that is moving increasingly towards digitalization and decentralization, it remains

[Read More »](#)



Kayentis operational excellence

23 January 2024

Why do customers recommend Kayentis for operational excellence? More than 95% of Kayentis customers recommend

[Read More »](#)




Innovation and Partnerships: The Biotech Perspective

16 January 2024

In the ever-evolving landscape of biotechnology, groundbreaking advancements continue to shape the future of healthcare.

[Read More »](#)



Exploring The Specific Challenges Of Pediatric Clinical Trials – Insights From Site Experts

22 November 2023

In this first episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)